← All trials
NCT05686161
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2022
- Primary completion
- Dec 7, 2022
- Completion date
- Jun 27, 2023
- First posted
- Jan 17, 2023
- Last posted
- Jan 17, 2023
- Enrollment
- 600
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stemirna TherapeuticsLead sponsor
- Government of CambodiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.